# Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.

> **NCT02581995** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 560 (actual)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02581995
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-19
- **Primary completion:** 2017-08-09
- **Final completion:** 2017-08-09
- **Target enrollment:** 560 (ACTUAL)
- **Last updated:** 2018-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581995, "Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02581995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*